CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBay’s expectations. The company tested its drug in patients with primary biliary cholangitis, a chronic inflammatory disease that slowly destroys the liver. After a year, the company tested levels of enzymes related to liver damage. Almost 62% of patients who received CymaBay’s drug, dubbed seladelpar, saw lower enzyme levels, compared with 20% of placebo recipients. 12 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for CymaBay Therapeutics in the last year.
Healthcare Stocks Moving Up and Down Friday: BXRX, VBIV, RNLX, CBAY, UNCY, APYX, PETV, PSTV – InvestorsObserver
Healthcare Stocks Moving Up and Down Friday: BXRX, VBIV, RNLX, CBAY, UNCY, APYX, PETV, PSTV.
Posted: Fri, 30 Jun 2023 07:00:00 GMT [source]
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat’s FREE daily newsletter.
Related News CBAY
CymaBay Therapeutics’ stock is owned by a variety of institutional and retail investors. Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Paul T Quinlan and Sujal Shah. CymaBay Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 8,960,000 shares, a decline of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 3.7 days.
On a nine-point scale measuring itch symptoms, seladelpar recipients had an average reduction of 3.2 points compared with just 1.7 points in the placebo group. One quarter of patients reached normal enzyme levels, indicating liver damage had stopped. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Get this delivered to your inbox, and more info about our products and services. Additional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients Preclinical data… Evaluates seladelpar 10 mg vs. placebo for alkaline phosphatase normalization at 52 weeks Patients enroll with alkaline phosphatase levels between 1- and 1.67-times upper limit of normal NEWARK, Calif… The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from https://1investing.in/ these return calculations. According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 11 buy ratings and 1 strong buy rating for CBAY.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. CymaBay difference between villa and bungalow Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics.
Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
CymaBay Therapeutics Consensus Rating and Price Target (
They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.64, a 26.33% upside from current levels.
The announcement comes less than a week after CymaBay reported highly encouraging results from a phase 3 clinical trial of seladelpar. In the trial, the drug met all its primary and secondary endpoints. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.
CymaBay Therapeutics’ Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
Bullishly for CBAY stock, there were no serious side effects related to seladelpar in the study. Side effects and patient discontinuations were consistent across patients who received the drug and those given the placebo, CymaBay said in a news release. But after six months of treatment, patients treated with seladelpar had a statistically significant reduction in itching vs. the placebo group.
- The company was founded on October 5, 1988 and is headquartered in Newark, CA.
- Upgrade to MarketBeat All Access to add more stocks to your watchlist.
- CymaBay Therapeutics’ stock is owned by a variety of institutional and retail investors.
- CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
The average twelve-month price prediction for CymaBay Therapeutics is $19.18 with a high price target of $33.00 and a low price target of $12.00. This press release contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the timing of the closing of the public offering and anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all.
About MarketBeat
According to TipRanks, Kim PhD has an average return of 7.8% and a 40.91% success rate on recommended stocks. Analysts like CymaBay Therapeutics more than other Medical companies. The consensus rating for CymaBay Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This puts its shares in the top 1% of all stocks when it comes to 12-month performance. On a year-to-date basis, CBAY stock has soared more than 159%.
It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. 12 Wall Street research analysts have issued 1-year target prices for CymaBay Therapeutics’ stock. Their CBAY share price forecasts range from $12.00 to $33.00. On average, they predict the company’s stock price to reach $19.18 in the next twelve months. This suggests a possible upside of 13.4% from the stock’s current price.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Compare
CBAY’s historical performance
against its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
That could help differentiate CymaBay’s drug from Intercept’s approved medicine, Ocaliva, and another experimental drug from Genfit called elafibranor. Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay Therapeutics’ (CBAY) experimental liver-disease treatment to rivals from Intercept Pharmaceuticals (ICPT) and Genfit (GNFT). CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage study of seladelpar, its investigational treatment for the rare … CymaBay Therapeutics’ stock was trading at $6.27 on January 1st, 2023. Since then, CBAY shares have increased by 169.7% and is now trading at $16.91.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. CymaBay said that the funds raised will be channeled into the development of its investigational drug seladelpar, which targets a rare chronic inflammatory liver affliction called primary biliary cholangitis (PBC). The monies will be used for clinical trials, the company’s working capital, and “general corporate purposes.” At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” CBAY shares. JonesTrading analyst Sean Kim PhD reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $19.00. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes. High-growth stocks tend to represent the technology, healthcare, and communications sectors.
The Motley Fool has no position in any of the stocks mentioned. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CBAY’s beta can be found in Trading Information at the top of this page.
- CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage study of seladelpar, its investigational treatment for the rare …
- Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
- The monthly returns are then compounded to arrive at the annual return.
- More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CBAY in relation to earlier this year. Last month, Menold Daniel, the VP Finance of CBAY bought 15,500.00 shares for a total of $79,010.00.